How Guardant Is Redefining Cancer Detection

Guardant Health’s co-founder and CEO, Helmy Eltoukhy reveals how the company has been making huge waves in the field of liquid biopsy.

Omar Ford

September 9, 2022

1 Min Read
IMG_2022-9-9-035029.png

For the past 10 years, Guardant Health has been defining the liquid biopsy space and has been a pioneer of sorts in the cancer detection market. The private company was one of the first in the space to go public and has secured a few FDA approvals to boot.

Guardant’s CEO and Co-founder Helmy Eltoukhy joins us for this episode of Let’s Talk Medtech to discuss the company’s past, present, and future. We also discuss the evolution of liquid biopsy and why the method holds so much promise for cancer detection.

About the Author

Omar Ford

Omar Ford is a veteran reporter in the field of medical technology and healthcare journalism. As Editor-in-Chief of MD+DI (Medical Device and Diagnostics Industry), a leading publication in the industry, Ford has established himself as an authoritative voice and a trusted source of information.

Ford, who has a bachelor's degree in print journalism from the University of South Carolina, has dedicated his career to reporting on the latest advancements and trends in the medical device and diagnostic sector.

During his tenure at MD+DI, Ford has covered a wide range of topics, including emerging medical technologies, regulatory developments, market trends, and the rise of artificial intelligence. He has interviewed influential leaders and key opinion leaders in the field, providing readers with valuable perspectives and expert analysis.

 

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like